Prophylactic therapy in haemophilia

Blood Reviews

Volumn 23, Issue 6, 2009, Pages 267-274

  Ljung, Rolf ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Factor IX; Factor VIII; Haemophilia A; Haemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTHROPATHY; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; FOLLOW UP; HEALTH CARE SYSTEM; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SECONDARY PREVENTION; TREATMENT RESPONSE; X RAY;

HEMOPHILIA A; HUMANS;

EID: 70349961526     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.08.001     Document Type: Article

References (83)

1. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 171 (1962) 237-242
2. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl Suppl 77 (1965) 3-132
3. Chambost H., and Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 11 (2005) 92-99
4. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 12 (2006) 124-127
5. Ota S., McLimont M., Carcao M.D., Blanchette V.S., Graham N., Paradis E., et al. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia 13 (2007) 12-20
6. Geraghty S., Dunkley T., Harrington C., Lindvall K., Maahs J., and Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 12 (2006) 75-81
7. Nilsson I.M., Berntorp E., Lofqvist T., and Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 232 (1992) 25-32
8. Nilsson I.M. Management of haemophilia in Sweden. Thromb Haemost 35 (1976) 510-521
9. Blomback M., and Nilsson I.M. Treatment of hemophilia A with human antihemophilic globulin. Acta Med Scand 161 (1958) 301-321
10. Ljung R.C. Aspects of haemophilia prophylaxis in Sweden. Haemophilia 8 Suppl 2 (2002) 34-37
11. Petrini P., Lindvall N., Egberg N., and Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 13 (1991) 280-287
12. van Creveld S. Prophylaxis in haemophilia. Lancet 1 (1971) 450
13. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 45 (1971) 120-127
14. van den Berg H.M., Fischer K., Mauser-Bunschoten E.P., Beek F.J., Roosendaal G., van der Bom J.G., et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 112 (2001) 561-565
15. Lofqvist T., Nilsson I.M., Berntorp E., and Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Int Med 241 (1997) 395-400
16. Kreuz W., Escuriola Ettingshausen C., Funk M., Pons S., Schmidt H., and Kornhuber B. Prevention of joint damage in hemophilic children with early prophylaxis. Orthopade 28 (1999) 341-346
17. Aledort L.M., Haschmeyer R.H., and Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Int Med 236 (1994) 391-399
18. Steen Carlsson K., Hojgard S., Glomstein A., Lethagen S., Schulman S., Tengborn L., et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 9 (2003) 555-566
19. Fischer K., van der Bom J.G., Molho P., Negrier C., Mauser-Bunschoten E.P., Roosendaal G., et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 8 (2002) 745-752
20. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005: CD003429.
21. Aledort L., Ljung R., and Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost 4 (2006) 503-504
22. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357 (2007) 535-544
23. Lundin B., Ljung R., and Pettersson H. MRI scores of ankle joints in children with haemophilia - comparison with clinical data. Haemophilia 11 (2005) 116-122
24. Kreuz W., Escuriola-Ettingshausen C., Funk M., Schmidt H., and Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia 4 (1998) 413-417
25. Pettersson H., Ahlberg A., and Nilsson I.M. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res (1980) 153-159
26. Soreff J., and Blomback M. Arthropathy in children with severe hemophilia A. Acta Paediatr Scand 69 (1980) 667-673
27. Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia. 9 Suppl 1 (2003) 38-42 [discussion 3]
28. Fischer K., Astermark J., van der Bom J.G., Ljung R., Berntorp E., Grobbee D.E., et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 8 (2002) 753-760
29. Ljung R., Aronis-Vournas S., Kurnik-Auberger K., van den Berg M., Chambost H., Claeyssens S., et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 6 (2000) 619-624
30. Astermark J., Petrini P., Tengborn L., Schulman S., Ljung R., and Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 105 (1999) 1109-1113
31. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 138 (2007) 580-586
32. Ljung R. Paediatric care of the child with haemophilia. Haemophilia 8 (2002) 178-182
33. Petrini P. Treatment strategies in children with hemophilia. Paediatr Drugs 4 (2002) 427-437
34. Petrini P., Chambost H., and Nemes L. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia 10 Suppl 4 (2004) 94-96
35. Santagostino E., Gringeri A., Berardinelli L., Beretta C., Muca-Perja M., and Mannucci P.M. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 123 (2003) 502-506
36. Feldman B.M., Pai M., Rivard G.E., Israels S., Poon M.C., Demers C., et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 4 (2006) 1228-1236
37. Ahnstrom J., Berntorp E., Lindvall K., and Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 10 (2004) 689-697
38. Ljung R.C. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 140 (2008) 378-384
39. Stieltjes N., Calvez T., Demiguel V., Torchet M.F., Briquel M.E., Fressinaud E., et al. Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 11 (2005) 452-458
40. Traivaree C., Blanchette V., Armstrong D., Floros G., Stain A.M., and Carcao M.D. Intracranial bleeding in haemophilia beyond the neonatal period - the role of CT imaging in suspected intracranial bleeding. Haemophilia 13 (2007) 552-559
41. Antunes S.V., Vicari P., Cavalheiro S., and Bordin J.O. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 9 (2003) 573-577
42. Revel-Vilk S., Golomb M.R., Achonu C., Stain A.M., Armstrong D., Barnes M.A., et al. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr 144 (2004) 490-495
43. Giroud M., Milan C., and Beuriat P. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infartcs, lacunes and transient ischaemic attacks. The stroke Registry of Dijon: 1985-1989. Int J Epidemiol 20 (2001) 892-899
44. Nilsson O.G., Lindgren A.C., Stahl N., Brandt L., and Säveland H. Incidence of intracerebral and subarachnoidal haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatr 69 (2000) 601-607
45. Arnold W.D., and Hilgartner M.W. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 59 (1977) 287-305
46. Nuss R., Kilcoyne R., Geraghty S., Wilkins R., Wiedel J., and Manco-Johnson M. Magnetic resonance imaging visualization of hemorrhage into a suprapatellar pouch in a child with hemophilia. Am J Pediatr Hematol Oncol 16 (1994) 183-185
47. Nuss R., Kilcoyne R.F., Geraghty S., Shroyer A.L., Rosky J.W., Mawhinney S., et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 6 (2000) 162-169
48. Nuss R., Kilcoyne R.F., Geraghty S., Wiedel J., and Manco-Johnson M. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. J Pediatr 123 (1993) 388-392
49. Nuss R., Kilcoyne R.F., Rivard G.E., and Murphy J. Late clinical, plain X-ray and magnetic resonance imaging findings in haemophilic joints treated with radiosynoviorthesis. Haemophilia 6 (2000) 658-663
50. Lundin B., Babyn P., Doria A.S., Kilcoyne R., Ljung R., Miller S., et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 11 (2005) 109-115
51. Lundin B., Pettersson H., and Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 10 (2004) 383-389
52. Funk M.B., Schmidt H., Becker S., Escuriola C., Klarmann D., Klingebiel T., et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 8 (2002) 98-103
53. Kilcoyne R.F., and Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 9 Suppl 1 (2003) 57-63 [discussion-4]
54. Soler R., Lopez-Fernandez F., Rodriguez E., and Marini M. Hemophilic arthropathy. A scoring system for magnetic resonance imaging. Eur Radiol. 12 (2002) 836-843
55. Dobon M., Lucia J.F., Aguilar C., Mayayo E., Roca M., Solano V., et al. Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia 9 (2003) 76-85
56. Nuss R., and Kilcoyne R. The MRI atlas of hemophilic arthropathy (2002), Professional Publishing Group, Ltd., New York
57. Gilbert M.S. Prophylaxis: musculoskeletal evaluation. Semin Hematol 30 (1993) 3-6
58. Hilliard P., Funk S., Zourikian N., Bergstrom B.M., Bradley C.S., McLimont M., et al. Hemophilia joint health score reliability study. Haemophilia 12 (2006) 518-525
59. van Genderen F.R., van Meeteren N.L., van der Bom J.G., Heijnen L., de Kleijn P., van den Berg H.M., et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 10 (2004) 565-571
60. Poonnoose P.M., Manigandan C., Thomas R., Shyamkumar N.K., Kavitha M.L., Bhattacharji S., et al. Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia 11 (2005) 598-602
61. von Mackensen S., and Bullinger M. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 10 Suppl 1 (2004) 17-25
62. Young N.L., Bradley C.S., Wakefield C.D., Barnard D., Blanchette V.S., and McCusker P.J. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?. Pediatr Blood Cancer 47 (2006) 305-311
63. Bullinger M., and von Mackensen S. Quality of life assessment in haemophilia. Haemophilia 10 Suppl 1 (2004) 9-16
64. Bohn R.L., Schramm W., Bullinger M., Van den Berg M., and Blanchette V. Outcome measures in haemophilia: more than just factor levels. Haemophilia 10 Suppl 1 (2004) 2-8
65. Beeton K., De Kleijn P., Hilliard P., Funk S., Zourikian N., Bergstrom B.M., et al. Recent developments in clinimetric instruments. Haemophilia 12 Suppl 3 (2006) 102-107
66. Morado M., Villar A., Jimenez Yuste V., Quintana M., and Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 11 (2005) 79-83
67. Santagostino E., Mancuso M.E., Rocino A., Mancuso G., Mazzucconi M.G., Tagliaferri A., et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 130 (2005) 422-427
68. Gouw S.C., van der Bom J.G., and van den Berg H.M. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109 (2007) 4648-4654
69. Valentino L.A. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 12 Suppl 5 (2006) 26-31
70. Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 4 (2006) 2498-2500
71. Konkle B.A., Ebbesen L.S., Erhardtsen E., Bianco R.P., Lissitchkov T., Rusen L., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5 (2007) 1904-1913
72. Hoots W.K., Ebbesen L.S., Konkle B.A., Auerswald G.K., Roberts H.R., Weatherall J., et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia (2008)
73. Richards M., Altisent C., Batorova A., Chambost H., Dolan G., de Moerloose P., et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 13 (2007) 473-479
74. Fischer K., van der Bom J.G., Mauser-Bunschoten E.P., Roosendaal G., Prejs R., de Kleijn P., et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 99 (2002) 2337-2341
75. Fischer K., Van Der Bom J.G., Prejs R., Mauser-Bunschoten E.P., Roosendaal G., Grobbee D.E., et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 7 (2001) 544-550
76. van Dijk K., Fischer K., van der Bom J.G., Scheibel E., Ingerslev J., and van den Berg H.M. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 130 (2005) 107-112
77. Biss T.T., Chan A.K., Blanchette V.S., Iwenofu L.N., McLimont M., and Carcao M.D. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 14 (2008) 923-930
78. Ljung R.C. Can haemophilic arthropathy be prevented?. Br J Haematol 101 (1998) 215-219
79. Tagliaferri A., Franchini M., Coppola A., Rivolta G.F., Santoro C., Rossetti G., et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 14 (2008) 945-951
80. Schramm W., Royal S., Kroner B., Berntorp E., Giangrande P., Ludlam C., et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 8 (2002) 33-43
81. Schramm W., and Berger K. Economics of prophylactic treatment. Haemophilia 9 Suppl 1 (2003) 111-115 [dicussion 6]
82. Bohn R.L., and Avorn J. Cost-effectiveness - can it be measured?. Semin Hematol 30 (1993) 20-23
83. Miners A.H., Sabin C.A., Tolley K.H., and Lee C.A. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 20 (2002) 759-774